Table 2.
Factors independently predictive of development of VOD in multivariate analysis
| Variable | N | OR (95% CI) | p-value |
|---|---|---|---|
| Aee: OR of developing VOD corresponding to a 1 year decrease in age within each stratum | |||
| <10 years age group | 944 | 1.10(1.03–1.17) | 0.004 |
| 10–19 years age group | 604 | 1.01 (0.95–1.07) | 0.81 |
| 20–39 years age group | 1128 | 1.04(1.01–1.08) | 0.01 |
| 40–59 years age group | 2184 | 1.01(0.98–1.04) | 0.61 |
| ≥60 years age group | 1242 | 1.05(0.96–1.16) | 0.28 |
| Karnofsky | 0.007 | ||
| <90 | 1901 | 1.47(1.11–1.94) | |
| Hepatitis Serology | 0.005 | ||
| Hepatitis B/C negative | 5799 | 1.00 | |
| Hepatitis C positive | 42 | 0.45 (0.06–3.68) | 0.46 |
| Hepatitis B/C positive or Hep B positive | 261 | 2.19(1.35–3.56) | 0.002 |
| Disease/Disease Status | 0.04 | ||
| Inherited problems of metabolism | 119 | 1.00 | |
| Acute Lymphoblastic Leukemia Early1/Missing | 427 | 1.96(0.73–5.25) | 0.18 |
| Acute Lymphoblastic Leukemia Intermediate2 | 316 | 2.03 (0.75–5.50) | 0.16 |
| Acute Lymphoblastic Leukemia Advanced3 | 70 | 2.04 (0.47–8.83) | 0.34 |
| Severe Combined Immunodeficiency Disease | 177 | 2.21 (0.87–5.63) | 0.10 |
| Other leukemias4 | 256 | 2.23 (0.65–7.67) | 0.21 |
| Chronic Myeloid Leukemia Early5/lntermediate6 | 164 | 2.50(0.77–8.12) | 0.13 |
| Multiple Myeloma | 59 | 2.52 (0.28–22.26) | 0.41 |
| NHL/HD Primary Induction Failure-Resistant | 39 | 2.61(0.29–23.24) | 0.39 |
| NHL/HD PIF/REL Sensitive, CR, untreated | 448 | 2.68 (0.92–7.78) | 0.07 |
| Acute Myeloid Leukemia Early1/Intermediate2 | 1760 | 2.84(1.21 −6.64) | 0.02 |
| Acute Myeloid Leukemia Advanced3/ Missing | 494 | 3.06(1.19–7.87) | 0.02 |
| Histiocytic disorders | 80 | 3.34(1.17–9.48) | 0.02 |
| Aplastic Anemia/Abnormalities of Erythrocytes | 398 | 3.37(1.33–8.54) | 0.01 |
| Myelodysplastic syndromes Early/Advanced | 853 | 4.15(1.67–10.33) | 0.002 |
| Chronic Myeloid Leukemia Advanced7 | 53 | 5.22(1.37–19.97) | 0.02 |
| Myeloproliferative Syndromes | 339 | 6.24(2.47–15.78) | <0.001 |
| NHL/HD Relapse Resistant | 50 | 7.34(1.66–32.32) | 0.009 |
| Conditioning Regimen | <0.001 | ||
| RIC-Chemo: Bu ± others | 637 | 1.00 | |
| RIC-Chemo: Mel ± Others or BEAM/CBV like | 589 | 1.01(0.42–2.45) | 0.98 |
| MAC-Chemo: Thio ± others | 118 | 1.06(0.27–4.08) | 0.94 |
| NST or No regimen | 961 | 1.08(0.47–2.52) | 0.85 |
| RIC-TBI | 170 | 1.22(0.36–4.11) | 0.75 |
| MAC-Chemo: Bu/Cy no PK monitoring | 409 | 1.90(0.79–4.59) | 0.15 |
| MAC-TBI: <=12 Gy TBI/Cy | 495 | 2.04 (0.84–4.97) | 0.12 |
| MAC-TBI: >12 Gy TBI/Cy | 321 | 2.13(0.87–5.23) | 0.10 |
| MAC-Chemo: Bu/Cy/Others no PK | 53 | 2.38 (0.72–7.96) | 0.16 |
| MAC-Chemo: Bu/Mel ± Others no PK | 15 | 2.45 (0.27–22.30) | 0.42 |
| MAC-TBI: <=12 Gy TBI ± Others | 108 | 2.56 (0.80–8.20) | 0.11 |
| MAC-Chemo: Bu/Flu/Others no PK | 46 | 2.69(0.55–13.22) | k 0.22 |
| MAC-TBI: >12 Gy TBI/Cy/Others | 336 | 3.07(1.30–7.22) | 0.01 |
| MAC-Chemo: Bu/Flu no PK | 292 | 3.52(1.51 −8.25) | 0.003 |
| MAC-TBI: >12 Gy TBI ± Others | 107 | 3.56(1.16–10.92) | 0.02 |
| MAC-Chemo: Bu ± Others no PK | 47 | 3.89(0.96–15.70) | 0.06 |
| MAC-Chemo: Bu/Flu with PK | 413 | 4.01(1.83–8.76) | <0.001 |
| MAC-TBI: <=12Gy TBI/Cy/Others | 236 | 4.37(1.82–10.48) | 0.001 |
| MAC-Chemo: Bu/Cy with PK | 552 | 4.52(2.10–9.74) | <0.001 |
| MAC-Chemo: Bu/Cy/Others with PK | 85 | 5.22(2.09–13.07) | <0.001 |
| MAC-Chemo: Bu ± Others with PK | 27 | 6.74(1.93–23.56) | 0.003 |
| MAC-Chemo: Bu/Mel ± Others with PK | 45 | 7.44 (2.49–22.28) | O.001 |
| MAC-Chemo: Bu/Flu/Others with PK | 40 | 8.09(2.46–26.59) | <0.001 |
| Sirolimus Use | |||
| Yes | 478 | 2.39(1.54–3.71) | <0.001 |
Abbreviations: BEAM=carmustine, etoposide, cytarabine, melphalan; Bu=busulfan; CBV= cyclophosphamide, carmustine, etoposide; Cy=cyclophosphamide; Flu=fludarabine; HD=Hodgkin Disease; MAC=myeloablative conditioning; Mel=melphalan; NHL=Non-hodgkin Lymphoma; NST=Nonmyeloablative stem cell transplantation; PIF=primary induction failure; PK=pharmacokinetic; RIC=reduced intensity conditioning; Thio=thiotepa; TBI=total body irradiation;
Early: CR1
Intermediate: CR2+
Advanced: Active Leukemia
Other Leukemias included: CLL, NOS; hairy cell leukemia; other leukemia, specify; CLL B-cell; CLL T-cell; PLL B cell; PLL T cell
Early: Chronic phase 1, hematologic complete remission
Intermediate: Chronic phase 2+
Advanced: Accelerated phase, blast crisis